Market Place
Sourcing Support
All News #Library
Biotech
Cocrystal Pharma Reveals 2025 Financials, Updates Antiviral Drug
31 Mar 2026 //
GLOBENEWSWIRE
Cocrystal Pharma Initiates Phase 1B Study On CDI-988
09 Mar 2026 //
GLOBENEWSWIRE
Cocrystal’s First Oral Norovirus Protease Inhibitor CDI-988
19 Feb 2026 //
GLOBENEWSWIRE
Cocrystal Pharma Gets Emory Med School Approval For CDI-988
18 Dec 2025 //
GLOBENEWSWIRE
Cocrystal Pharma Reveals Q3 2025 Financials & Pipeline Updates
14 Nov 2025 //
GLOBENEWSWIRE
Cocrystal Pharma Secures NIH SBIR Award For Advancing Influenza
27 Oct 2025 //
GLOBENEWSWIRE
Cocrystal Presents 1st Oral CDI-988 for Norovirus at Conference
12 Sep 2025 //
GLOBENEWSWIRE
Cocrystal Presents Ph 1 Results for CDI-988 at DoD Med Conference
05 Aug 2025 //
GLOBENEWSWIRE
Cocrystal`s Norovirus Antiviral Show Activity Against GII.17 Variant
24 Apr 2025 //
GLOBENEWSWIRE
Cocrystal Reports Ph 1 Results For Antiviral CDI-988 Against Viruse
08 Jan 2025 //
GLOBENEWSWIRE
Cocrystal Co-CEOs Discuss Antiviral Drug Approach for Flu & COVID
31 Oct 2024 //
GLOBENEWSWIRE
Cocrystal Pharma Advances CDI-988 Into Phase 1 Dose Cohorts
26 Sep 2024 //
GLOBENEWSWIRE
CoCrystal Pharma To Present At August 20th Virtual Investor Summit Microcap
15 Aug 2024 //
ACCESSWIRE
Cocrystal receives approval from HREC for Phase I trial of Covid-19 therapy
01 Jun 2023 //
CLINICAL TRIALS ARENA
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.